Reviva Pharmaceuticals Holdings Inc.

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

Reviva Announces Letter to Shareholders

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia